Radiopharm Theranostics Limited · ASX:RAD
Radiopharm Theranostics — Shareholder Meeting (November 2025)
22 slides from Radiopharm Theranostics's shareholder meeting presentation, Nov 20, 2025
Slide 1: Annual General Meeting
For personal use only NASDAQ: RADX / ASX: RAD Annual General Meeting NOVEMBER 20 , 2025
Slide 2: Notice & Disclaimer
Notice & Disclaimer The information in this presentation does not constitute personal investment advice. The presentation is not intended to be comprehensive or provide all information required by investors to make an informed decision on any investment in Radiopharm Theranostics Ltd ACN 647 877 889
Slide 3: Investments Highlights
Investments Highlights Clinical Stage Company Advancing First-in-Class Radiopharmaceuticals For personal use only • Five priority molecules; 4 Therapeutics (PD-L1; HER2; B7H3; KLK3) and 1 Diagnostics (Brain Mets) Secure Supply Chain • Redundant and secure radioisotopes supply chains (Lu177 & Tb161)
Slide 4: Company Priorities – Five first-in-class radiopharmaceutical molecules
Company Priorities – Five first-in-class radiopharmaceutical molecules PROGRAM TARGET & MOLECULE INDICATION ISOTOPE PRECLINICAL PHASE I PHASE IIA PHASE IIB November updates in yellow For personal use only IMAGING TRIAL Short Chain Fatty Acid Phase 2b in 5 US centers, NCT06777433 RAD101 Brain Mets F1
Slide 5: RAD Imaging: Clinical Development
RAD 101 DIAGNOSTIC RAD 101 Imaging: Clinical Development Phase IIb imaging study currently recruiting in five centers in USA: 50% enrolment achieved For personal use only No competitor identified; RAD 101 is the only PET agent in clinical development for Brain Mets Large Total addressable market: 30
Slide 6: Clinical Data from Phase IIb
RAD 101 DIAGNOSTIC Clinical Data from Phase IIb For personal use only • Images from n=3 subjects in the ongoing study released • Showing increased metabolic activity in areas with equivocal MRI findings (suspected relapse) • N=15 subjects dosed as of 11/17/2025 6
Slide 7: Next Steps
RAD 101 DIAGNOSTIC Next Steps Phase IIb For personal use only • 11 patient data to be released by Q1 2026 • Trial completion N=30/30 pts by Q1 2026 • Phase 2b readout in the first half of 2026 Phase III • FDA Meeting to align on Phase III - mid 2026 • Phase III start – Q4 2026 7
Slide 8: RAD101 Commercial Potential
RAD 101 DIAGNOSTIC RAD101 COMMERCIAL POTENTIAL: USD$ >500m yearly sales (USA only) Third largest imaging molecule after Pilarify (Lantheus) & Illucix (Telix) For personal use only Year 1 Year 2 Year 3 Year 4 Year 5 Year 6 Year 7 Year 8 8
Slide 9: Molecule: 177Lu-RAD204
RAD 204 THERAPEUTIC For personal use only Molecule: 177Lu-RAD204 Targeting MoA: PD-L1 Therapeutic for: PD-L1+ TUMORS 9
Slide 10: Phase Trial Design
RAD 204 THERAPEUTIC Phase 1 Trial Design 177Lu-anti-PD-L1 single domain AB in metastatic solid tumors Dose Level Dose Primary Objectives For personal use only o Safety and tolerability of 177Lu-RAD204 Phase 0 o Recommended ph2 dose of 177Lu-RAD204tr (Imaging Period with Imaging dose 10 (0.37 GBq) 17
Slide 11: Clinical data Phase I
RAD 204 THERAPEUTIC Clinical data Phase I • First (30mCi) and Second Cohort (60mCi) completed, and 6 patient data released. For personal use only • Tumor uptake confirmed in all the treated subjects. No tumor reduction above 30% achieved at the first two dose levels • The safety profile has been ver
Slide 12: Tumor Uptake: Significant increase at DL2 vs DL1
RAD 204 THERAPEUTIC Tumor Uptake| Significant increase at DL2 vs DL1 For personal use only COHORT#1 COHORT#2 180 4 160 3.5 Average Average Absorbed dose Absorbed dose 140 at 30 mCi at 60 mCi 3 120 Dose (Gy), Dose (Gy), 2.5 Lu177 mCi Patients Patients Tumor Gy with PVC1 with PVC1 100 90 2 #1 0.56 #4
Slide 13: Molecule: 177Lu-RAD202
RAD 202 THERAPEUTIC For personal use only Molecule: 177Lu-RAD202 Targeting MoA: HER2 Therapeutic for: HER2+ TUMORS 13
Slide 14: Phase Trial Design
RAD 202 THERAPEUTIC Phase 1 Trial Design ‘HEAT’ Trial (HER2 Antibody Therapy with Lutetium-177) in subjects with HER2+ advanced solid tumors Primary Objectives (Phase 1, Treatment): Dose Level Dose For personal use only o Safety and tolerability of 177Lu-RAD202 o Recommended ph2 dose of 177Lu-RAD202
Slide 15: Clinical Data Phase I
RAD 202 THERAPEUTIC Clinical Data Phase I • First Cohort completed (30 mCi), with 3 Patient data released For personal use only • Significant tumor uptake observed • The safety profile very favorable, with few low-grade adverse events and no SAEs observed thus far • Currently recruiting Cohort #2 at
Slide 16: Molecule: RV01/BetaBart
RV 01 THERAPEUTIC RAD 202 utilizes an anti-HER2 Nanobody as a targeting moiety For personal use only Molecule: RV01/BetaBart Targeting MoA: B7H3 Therapeutic for: Multiple Tumor Types 16
Slide 17: RV01 (Betabart) Key Milestones
RV01 THERAPEUTIC RV01 (Betabart) Key Milestones ACHIEVED For personal use only 1. Phase I therapeutic trial IND received in July 2025 Future Milestone 2. Basket Phase I therapeutic trial to start by the end of 2025 TARGET & 2ND HALF 1ST HALF 2ND HALF 1ST HALF PROGRAM INDICATION Dx/Tx ISOTOPE MOLECUL
Slide 18: Molecule: RAD 402 – 161Tb
RAD402 THERAPEUTIC RAD 202 utilizes an anti-HER2 Nanobody as a targeting moiety For personal use only Molecule: RAD 402 – 161Tb Targeting MoA: KLK3 Therapeutic for: PROSTATE CANCER 18
Slide 19: RAD – mAb targeting KLK3 in Prostate Cancer
RAD402 THERAPEUTIC RAD 402 – mAb targeting KLK3 in Prostate Cancer KLK3 is expressed only in prostate. PSMA has more off-target affinity For personal use only 1. RAD 402 is a humanized IgG1 internalized by prostate cells, KLK3 specifically binding KLK3 with high affinity PSMA 2. RAD 402 has highly s
Slide 20: RAD402 Key Milestones
RAD402 THERAPEUTIC RAD 402 – Key Milestones 1. Ethics Committee approval in Q4 2025 For personal use only 2. Phase I therapeutic trial in Australia to start in Q4 2025 TARGET & 2ND HALF 1ST HALF 2ND HALF PROGRAM INDICATION Dx/Tx ISOTOPE MOLECULE 2024 2025 2025 Ethics Committee KLK3 Approval RAD402 P
Slide 21: Company Priorities – Five first-in-class radiopharmaceutical molecules
Company Priorities – Five first-in-class radiopharmaceutical molecules PROGRAM TARGET & MOLECULE INDICATION ISOTOPE PRECLINICAL PHASE I PHASE IIA PHASE IIB November updates in yellow For personal use only IMAGING TRIAL Short Chain Fatty Acid Phase 2b in 5 US centers, NCT06777433 RAD101 Brain Mets F1
Slide 22: Thank You
For personal use only Thank You www.radiopharmtheranostics.com 22
Radiopharm Theranostics — Shareholder Meeting (November 2025) on 6ix